Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;2012:639561.
doi: 10.1155/2012/639561. Epub 2012 Apr 8.

Alternative Blood Products and Clinical Needs in Transfusion Medicine

Affiliations
Free PMC article

Alternative Blood Products and Clinical Needs in Transfusion Medicine

Carolyn Whitsett et al. Stem Cells Int. .
Free PMC article

Abstract

The primary focus of national blood programs is the provision of a safe and adequate blood supply. This goal is dependent on regular voluntary donations and a regulatory infrastructure that establishes and enforces standards for blood safety. Progress in ex vivo expansion of blood cells from cell sources including peripheral blood, cord blood, induced pluripotent stem cells, and human embryonic stem cell lines will likely make alternative transfusion products available for clinical use in the near future. Initially, alloimmunized patients and individuals with rare blood types are most likely to benefit from alternative products. However, in developed nations voluntary blood donations are projected to be inadequate in the future as blood usage by individuals 60 years and older increases. In developing nations economic and political challenges may impede progress in attaining self-sufficiency. Under these circumstances, ex vivo generated red cells may be needed to supplement the general blood supply.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Sixth Announcement of the Transfusion Medicine Academic Award. http://grants.nih.gov/grants/guide/historical/1987_02_13_Vol_16_No_06.pdf.
    1. Snyder EL. Component therapy to cellular therapy and beyond—a Darwinian approach to transfusion medicine. Transfusion. 2008;48(9):2000–2007. - PubMed
    1. Mason C, Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regenerative Medicine. 2010;5(3):307–313. - PubMed
    1. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy. 2011;11(4):473–487. - PubMed
    1. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Current Opinion in Immunology. 2010;22(2):251–257. - PMC - PubMed

LinkOut - more resources

Feedback